Adaptimmune initiates Multiple Myeloma drug Phase I/II clinical trial
The dual site, two-cohort, open-label clinical trial is intended to assess the safety, bioactivity and anti tumor effect of infusion of patients’ own T cells that have been
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.